ReviewNature reviews. Neurology2015
Multiple sclerosis and pregnancy in the 'treatment era'.
Review in Nature reviews. Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 117 citations in OpenAlex.
- Motherhood choice in multiple sclerosis (MoMS) - Pilot trial of web-based decision support.PloS one · 2026Trial
- Parkinson's Spectrum Mechanisms in Pregnancy: Exploring Hypothetical Scenarios for MSA in the Era of ART.International journal of molecular sciences · 2025Review
- Sex differences in age-associated neurological diseases-A roadmap for reliable and high-yield research.Science advances · 2025Review
- Explaining the burden of cultural factors on MS disease: a qualitative study of the experiences of women with multiple sclerosis.BMC women's health · 2024Article
- Evaluation of ovarian reserve and the assisted reproductive technology (ART) cycles' outcome as well as the relapse rate within one year after ART in women with multiple sclerosis: a case-control study.Journal of ovarian research · 2024Article
- Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis.CNS drugs · 2023Review
- Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel.Neurology and therapy · 2023Review
- Explaining the burden of psychosocial factors on the worsening symptoms of MS: a qualitative study of patients' experiences.BMC neurology · 2023Article
- Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey.Frontiers in neurology · 2023Article
- Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA.Therapeutic advances in neurological disorders · 2023Article
- Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.Degenerative neurological and neuromuscular disease · 2022Review
- A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.Therapeutic advances in neurological disorders · 2021Review
- Effector T Helper Cells Are Selectively Controlled During Pregnancy and Related to a Postpartum Relapse in Multiple Sclerosis.Frontiers in immunology · 2021Article
- Family Planning Decision Making in People With Multiple Sclerosis.Frontiers in neurology · 2021Article
- Early Aggressive Treatment Approaches for Multiple Sclerosis.Current treatment options in neurology · 2021Review
- The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.The patient · 2020Article
- Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.Neurology. Clinical practice · 2020Article
- Pregnancy and Motherhood Concerns Surrounding Women with Multiple Sclerosis: A Qualitative Content Analysis.International journal of community based nursing and midwifery · 2020Article
- Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.Journal of drug assessment · 2020Article
- Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure.Therapeutic advances in neurological disorders · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The influence of pregnancy on the course of multiple sclerosis (MS) has long been controversial; until the end of 1990s, women with MS were discouraged from having children owing to a biased belief that pregnancy would worsen the disease course. Since the first large prospective study in 1998, counselling of women with MS has changed radically, and many patients have attained their desire of motherhood. Although many disease-modifying drugs have come to market in the past two decades, when used during pregnancy and lactation, their beneficial effects on the course of MS have to be balanced with fears concerning potential risks to the fetus or child. The wealth of treatment options and the various associated risks have created a growing need for counselling on family planning for women with MS. Most importantly, such counselling should address the concerns that women with MS might have regarding pregnancy. Second, as soon as a woman starts considering pregnancy, a treatment plan should be established. This plan needs to weigh the risk posed to the fetus by potentially harmful drug exposure, and the risk to the mother from a reappearance of disease activity. Finally, breastfeeding and treatment options after delivery should be discussed to outline the options for prevention of postpartum relapses, and the possible resumption of disease-modifying drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.